Analysts predict that Vaccinex Inc (NASDAQ:VCNX) will post earnings per share of ($0.70) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Vaccinex’s earnings. The firm is scheduled to issue its next earnings results on Wednesday, August 21st.
On average, analysts expect that Vaccinex will report full-year earnings of ($2.25) per share for the current fiscal year, with EPS estimates ranging from ($2.29) to ($2.21). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.08) to ($1.73). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Vaccinex.
Vaccinex (NASDAQ:VCNX) last issued its earnings results on Wednesday, May 15th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.04). The business had revenue of $0.09 million during the quarter.
Shares of VCNX stock opened at $6.80 on Tuesday. Vaccinex has a fifty-two week low of $3.32 and a fifty-two week high of $12.00. The stock has a market capitalization of $79.21 million and a price-to-earnings ratio of -1.31.
Several hedge funds and other institutional investors have recently modified their holdings of VCNX. Vanguard Group Inc acquired a new position in shares of Vaccinex during the 3rd quarter valued at about $341,000. Vanguard Group Inc. acquired a new position in shares of Vaccinex during the 3rd quarter valued at about $341,000. Bank of New York Mellon Corp acquired a new position in shares of Vaccinex during the 3rd quarter valued at about $124,000. Finally, Telemetry Investments L.L.C. increased its holdings in shares of Vaccinex by 26.3% during the 4th quarter. Telemetry Investments L.L.C. now owns 14,720 shares of the company’s stock valued at $54,000 after acquiring an additional 3,066 shares during the last quarter. 2.10% of the stock is currently owned by institutional investors and hedge funds.
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Featured Article: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.